Natriuretic Peptides and Assessment of Cardiovascular Disease Risk in Asymptomatic Persons

Area of Science:

• Cardiology
• Biomarkers
• Preventive Medicine

Background:

• Current cardiovascular disease (CVD) risk assessment tools for asymptomatic individuals are suboptimal.
• Existing methods often miss individuals who will develop CVD despite low- or intermediate-risk classification.
• Early detection and intervention in at-risk populations are crucial for effective CVD prevention.

Purpose of the Study:

• To evaluate the potential of natriuretic peptides in identifying individuals at risk for future cardiovascular events.
• To explore the utility of natriuretic peptides in detecting subclinical CVD.
• To determine optimal strategies for natriuretic peptide testing to maximize performance and cost-effectiveness.

Main Methods:

• Review of current literature on CVD risk assessment tools.
• Analysis of studies investigating natriuretic peptides for risk stratification.
• Exploration of combined risk marker approaches (biomarkers, genetic testing, imaging).

Main Results:

• Natriuretic peptides demonstrate potential for identifying individuals at risk for cardiovascular events.
• Natriuretic peptides may aid in the detection of subclinical CVD.
• Combined use of multiple risk markers, including natriuretic peptides, shows promise for refining risk assessment.

Conclusions:

• Natriuretic peptides offer a promising avenue for improving cardiovascular risk assessment in asymptomatic individuals.
• Targeted natriuretic peptide testing in specific subpopulations can enhance its utility and cost-effectiveness.
• Further cost-effectiveness and outcomes studies are needed to confirm the role of natriuretic peptides in CVD risk stratification.